Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vitro evaluation of recombinant FIX-FIAV in adult hemophilia A patient plasma
NL-OMON47946Completed
- Sponsor
- Erasmus MC
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of recombinant factor IX-FIAV in hemophilia A, sponsored by Erasmus MC. Primary endpoints: Lag time of thrombin generation, Thrombin peak and 2 more. Started Dec 2019; status: completed.
02
Drugs
recombinant factor IX-FIAV
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON47946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47946.